Mar. 06, 2023
Teijin Pharma Grants Global Exclusive Licens for Investigational Small Molecule Candidate in Kidney Disease
Teijin Pharma Limited
Press Contact
Corporate Communications
Teijin Limited
pr@teijin.co.jp
menu
- Business Fields
- Business Activities
Home > News Release > 2023 > Teijin Pharma Grants Global Exclusive Licens for Investigational Small Molecule Candidate in Kidney Disease
We use cookies to help improve your experience on our website. Clink on "Agree" to agree and proceed, or click on "See Details" for more information and settings of cookies.